Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for a diversified orthopedic device manufacturer with significant acquisition activity, as revenue growth, cash conversion, and leverage dynamics jointly reflect the company’s capacity to fund integration while maintaining profitability.

Composite Trajectory: Mixed

Revenue grew 7.2% in 2025 to $8,231.5M (10-K 2025-12-31, Consolidated Statements of Earnings), accelerating from 3.8% in 2024, driven by the Paragon 28 acquisition and market growth. However, operating profit fell 14.6% to $1,098.1M (10-K 2025-12-31, Consolidated Statements of Earnings) and net earnings declined 22.0% to $705.1M (10-K 2025-12-31, Consolidated Statements of Earnings), with operating margin compressing from 16.7% to 13.3% (10-K 2025-12-31, MD&A). Operating cash flow rebounded to $1,697.1M in 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows), but investing outflows surged to $1,975.7M due to $1,393.2M of acquisition spending (10-K 2025-12-31, Consolidated Statements of Cash Flows). Total debt rose 21.2% to $7,519.1M (10-K 2025-12-31, Consolidated Balance Sheets; Note 12), increasing leverage while equity grew only modestly. The combination of top-line expansion, profit deterioration, elevated acquisition spending, and rising leverage yields a mixed trajectory.

2. Red Flags

• Operating margin compressed from 17.3% (2023) to 16.7% (2024) to 13.3% (2025) despite revenue growth (10-K 2025-12-31, MD&A, Expenses as a Percent of Net Sales table).
• Net earnings declined for two consecutive years: $1,024.0M (2023) → $903.8M (2024) → $705.1M (2025) (10-K 2025-12-31, Consolidated Statements of Earnings).
• Long-term debt increased from $5,341.6M to $6,932.0M (+29.8%) and total debt from $6,204.6M to $7,519.1M (+21.2%) to fund Paragon 28 and Monogram acquisitions (10-K 2025-12-31, Consolidated Balance Sheets; Note 12).
• Inventory and instrument charges of approximately $170M related to product lines to be discontinued by 2032 were recognized in 2025 (10-K 2025-12-31, MD&A; Critical Accounting Estimates).
• Contingent consideration liability rose from $180.7M to $299.2M (10-K 2025-12-31, Note 8, Fair Value Measurements; Note 9).
• SG&A as a percentage of net sales increased from 38.2% to 39.6% (10-K 2025-12-31, MD&A, Expenses as a Percent of Net Sales table).
• Interest expense rose from $218.0M to $292.8M (+34.3%) due to higher average debt balances (10-K 2025-12-31, Consolidated Statements of Earnings; MD&A).
• Restructuring programs have been initiated in 2019, 2021, 2023, and 2025, with the 2025 plan expecting $155M in charges through 2027 (10-K 2025-12-31, Note 4; MD&A).
• Effective tax rate increased from 12.7% to 15.1% (10-K 2025-12-31, Consolidated Statements of Earnings; MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Net sales increased 7.2% to $8,231.5M in 2025 (10-K 2025-12-31, Consolidated Statements of Earnings), up from 3.8% growth in 2024, with all product categories and geographies contributing. However, operating profit fell 14.6% to $1,098.1M (10-K 2025-12-31, Consolidated Statements of Earnings) and net earnings dropped 22.0% to $705.1M (10-K 2025-12-31, Consolidated Statements of Earnings). Gross margin declined from 63.8% to 61.6% (10-K 2025-12-31, MD&A, Gross Margin table), driven by $170M inventory/instrument charges, tariffs, and acquisition inventory step-up. SG&A rose to 39.6% of sales from 38.2% (10-K 2025-12-31, MD&A, Expenses as a Percent of Net Sales table). Diluted EPS fell from $4.43 to $3.55 (10-K 2025-12-31, Consolidated Statements of Earnings). The divergence between revenue growth and profit contraction defines the mixed earnings trajectory.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Net cash provided by operating activities improved to $1,697.1M in 2025 from $1,499.4M in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows), recovering from a 2024 dip. However, cash used in investing activities surged to $1,975.7M from $888.1M, primarily due to $1,393.2M paid for Paragon 28 and Monogram acquisitions (10-K 2025-12-31, Consolidated Statements of Cash Flows). Financing activities provided $326.0M, driven by $2,492.1M of senior note issuances offset by $1,463.0M of redemptions and $487.0M of share repurchases (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capital expenditures) increased year-over-year, but the massive acquisition outlay and debt-funded financing inflows create a mixed picture of organic cash generation versus strategic deployment.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew 8.1% to $23,091.7M (10-K 2025-12-31, Consolidated Balance Sheets), with goodwill rising 11.1% to $9,947.1M and intangible assets increasing 2.6% to $4,717.3M due to acquisitions (10-K 2025-12-31, Consolidated Balance Sheets; Note 10). Total debt increased 21.2% to $7,519.1M (current portion $587.1M + long-term $6,932.0M) from $6,204.6M (10-K 2025-12-31, Consolidated Balance Sheets; Note 12). Stockholders’ equity rose modestly to $12,705.8M from $12,476.2M (10-K 2025-12-31, Consolidated Balance Sheets). The current ratio improved slightly to 1.98x from 1.91x (10-K 2025-12-31, Consolidated Balance Sheets). Cash and equivalents increased to $591.9M from $525.5M (10-K 2025-12-31, Consolidated Balance Sheets). Rising leverage and acquisition-related intangibles offset asset growth and liquidity maintenance, resulting in a mixed balance sheet trajectory.

6. Data Gaps

• Quarterly financial statements for 2026 (Q1 and Q2 10-Qs) were referenced but not provided in the filings, preventing quarterly trend analysis.
• Quarterly segment operating profit and net sales breakdowns for 2026 periods.
• Free cash flow after acquisition-related investing outflows for 2026 quarters.
• Detailed reconciliation of non-GAAP adjustments mentioned in MD&A (e.g., "adjusted" metrics) to GAAP for 2026 periods.
• Updated contingent consideration fair value movements and maximum payout ranges for 2026.
• IRS tax audit resolution timeline and potential cash impact beyond disclosed $85.9M transition tax liability.